Literature DB >> 28454459

Expression of CXCL12 and its receptor CXCR4 in patients with adenomyosis.

Juan Li1, Geping Yin1, Ming Chen1, Shujun Yang1, Aifang Wu1, Jing Liang1, Zheng Yuan1.   

Abstract

The aim of the present study was to investigate the role of chemokine (C-X-C motif) ligand 12 (CXCL12) and its receptor, chemokine (C-X-C motif) receptor 4 (CXCR4) in the pathogenesis of adenomyosis (AD). Immunohistochemistry and reverse transcription-quantitative polymerase chain reaction analysis were used to measure the protein and mRNA expression of CXCL12 and CXCR4 in eutopic endometrial and ectopic foci tissue samples. Samples from a total of 36 patients with AD (study group) were compared with endometrial tissue samples from 33 patients who underwent uterine fibroids surgery (control group) during the same period. All data are presented as the mean ± standard deviation and were analyzed with SPSS software (version 16.0). Analysis of variance was used for between group analysis and pairwise comparison was performed using Fisher's least significant difference post hoc test. The results of the present study revealed that CXCL12 and CXCR4 protein expression was significantly increased in ectopic foci tissue compared with eutopic endometrial tissue samples from patients with AD. CXCL12 and CXCR4 protein expression in ectopic foci and eutopic endometrial tissue samples were significantly increased compared with the control group (P<0.05 for between group comparisons). No significant differences were identified in CXCL12 and CXCR4 protein expression between the proliferative and secretory phases within each group. Furthermore, CXCL12 and CXCR4 mRNA expression was significantly increased in ectopic foci tissue and eutopic endometrial tissue compared with the control group (P<0.05 for between group comparisons). CXCL12 mRNA expression was markedly increased in ectopic foci tissue compared with eutopic endometrial tissue of patients with AD. The expression of CXCR4 mRNA was significantly increased in eutopic endometrial tissue compared with ectopic foci tissue and the control group (P<0.05 for between group comparisons). No significant differences were identified in CXCL12 and CXCR4 mRNA expression between proliferative and secretory phase within each group. In conclusion, CXCL12 and CXCR4 may induce the ectopia, and promote the spread and localized growth of endometrial cells in the development of AD.

Entities:  

Keywords:  CXCL12; CXCR4; adenomyosis; pathogenesis

Year:  2017        PMID: 28454459      PMCID: PMC5403167          DOI: 10.3892/ol.2017.5762

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.

Authors:  Wei Mo; Jian Chen; Amish Patel; Liang Zhang; Vincent Chau; Yanjiao Li; Woosung Cho; Kyun Lim; Jing Xu; Alexander J Lazar; Chad J Creighton; Svetlana Bolshakov; Renée M McKay; Dina Lev; Lu Q Le; Luis F Parada
Journal:  Cell       Date:  2013-02-21       Impact factor: 41.582

3.  L-22 enhances the invasiveness of endometrial stromal cells of adenomyosis in an autocrine manner.

Authors:  Qing Wang; Li Wang; Jun Shao; Yan Wang; Li-Ping Jin; Da-Jin Li; Ming-Qing Li
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

4.  CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas.

Authors:  Liborio Torregrossa; Riccardo Giannini; Nicla Borrelli; Elisa Sensi; Rosa Marina Melillo; Pietro Leocata; Gabriele Materazzi; Paolo Miccoli; Massimo Santoro; Fulvio Basolo
Journal:  Mod Pathol       Date:  2011-09-09       Impact factor: 7.842

5.  Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways.

Authors:  Chun-Yin Huang; Chun-Yi Lee; Meng-Yi Chen; Wei-Hung Yang; Ying-Hao Chen; Chia-Hao Chang; Horng-Chaung Hsu; Yi-Chin Fong; Chih-Hsin Tang
Journal:  J Cell Physiol       Date:  2009-10       Impact factor: 6.384

6.  Risk factors for adenomyosis.

Authors:  A Shrestha
Journal:  J Nepal Health Res Counc       Date:  2012-09

7.  CXC receptor-4 mRNA silencing abrogates CXCL12-induced migration of colorectal cancer cells.

Authors:  Claudia Rubie; Vilma O Frick; Pirus Ghadjar; Mathias Wagner; Christoph Justinger; Sabrina K Faust; Benjamin Vicinus; Stefan Gräber; Otto Kollmar; Martin K Schilling
Journal:  J Transl Med       Date:  2011-02-24       Impact factor: 5.531

8.  Synthesis and Cytotoxic Evaluation of Some Novel SulfonamideDerivativesAgainst a Few Human Cancer Cells.

Authors:  Mina Mirian; Afshin Zarghi; Sedighe Sadeghi; Parisa Tabaraki; Mojdeh Tavallaee; Orkideh Dadrass; Hojjat Sadeghi-Aliabadi
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

9.  Synthesis and cytotoxic evaluation of novel 3-substituted derivatives of 2-indolinone.

Authors:  Shaya Mokhtari; Mahmoud Mosaddegh; Maryam Hamzeloo Moghadam; Zohreh Soleymani; Saeideh Ghafari; Farzad Kobarfard
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

10.  The pathophysiology of endometriosis and adenomyosis: tissue injury and repair.

Authors:  G Leyendecker; L Wildt; G Mall
Journal:  Arch Gynecol Obstet       Date:  2009-07-31       Impact factor: 2.344

View more
  2 in total

1.  Women with adenomyosis are at higher risks of endometrial and thyroid cancers: A population-based historical cohort study.

Authors:  Chih-Ching Yeh; Fu-Hsiung Su; Chii-Ruey Tzeng; Chih-Hsin Muo; Wen-Chang Wang
Journal:  PLoS One       Date:  2018-03-09       Impact factor: 3.240

2.  Transcriptome analysis of eutopic endometrium in adenomyosis after GnRH agonist treatment.

Authors:  Jiao Tian; Nannan Kang; Junxia Wang; Haixiang Sun; Guijun Yan; Chenyang Huang; Jie Mei
Journal:  Reprod Biol Endocrinol       Date:  2022-01-12       Impact factor: 5.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.